Interferon beta-1a is indicated for the treatment of:
Interferon beta-1a should be discontinued in patients who develop progressive MS.
For this indication, competent medicine agencies globally authorize below treatments:
7.5 - 30 ug
From 7.5 To 30 ug once every 7 day(s)
The recommended dosage for the treatment of relapsing MS is 30 micrograms, administered by intramuscular (IM) injection once a week. No additional benefit has been shown by administering a higher dose (60 micrograms) once a week.
To help patients reduce the incidence and severity of flu-like symptoms, titration can be performed at the initiation of treatment. Titration using the pre-filled syringe can be achieved by initiating therapy on ¼ dose increments per week reaching the full dose (30 micrograms/week) by the fourth week.
An alternative titration schedule can be achieved by initiating therapy on approximately a ½ dose of interferon beta-1a once a week before increasing to the full dose. In order to obtain adequate efficacy, a dose of 30 micrograms once a week should be reached and maintained after the initial titration period.
Prior to injection and for an additional 24 hours after each injection, an antipyretic analgesic is advised to decrease flu-like symptoms associated with interferon beta-1a administration. These symptoms are usually present during the first few months of treatment.